Patryk Lipiński, Piotr Socha, Irena Jankowska, Anna Tylki-Szymańska
Journal: International journal of molecular sciences 2026;27(18):
PMID: 42794530
Transaldolase deficiency (TALDO-D) is an ultra-rare disorder of the non-oxidative pentose phosphate pathway with prominent liver disease and systemic accumulation of polyols and seven-carbon sugars. We systematically reviewed hepatic manifestations, molecular findings, genotype-phenotype relationships, and liver transplantation (LTx) experience. PubMed/MEDLINE and Europe PMC were searched from inception to 10 August 2026, with citation tracking; supplementary Scopus and Web of Science Core Collection searches were performed on 19 August and 1 September 2026, respectively. Twenty-nine primary clinical reports were included. Individual-patient reconciliation supported 51 genetically/biochemically confirmed patients as the primary analytic set; inclusion of one diagnostically uncertain patient with a homozygous in-frame TALDO1 variant reported as a variant of uncertain significance produced an upper-bound sensitivity set of 52. Seven patients underwent LTx. TALDO1 variants were heterogeneous, and intrafamilial and intragenotypic variability precluded reliable genotype-based prediction. LTx may provide organ-specific rescue for advanced liver disease, but persistent renal, endocrine, hematologic, and metabolic abnormalities require lifelong multisystem surveillance.
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.